Literature DB >> 33334907

Osimertinib plus Ramucirumab: The Best of Both Worlds?

Edward B Garon1.   

Abstract

Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation-positive non-small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation-positive patients. The accompanying article reports on a study combining osimertinib with ramucirumab.See related article by Yu et al., p. 992. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33334907      PMCID： PMC7887048          DOI： 10.1158/1078-0432.CCR-20-4026

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  13 in total

1.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Authors:  Yi-Long Wu; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Fumito Tsuji; Rolf Linke; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Eric I Sbar; Tao Wang; Jane Liang White; Sashi Nadanaciva; Rickard Sandin; Tony S Mok
Journal:  Lancet Oncol       Date:  2017-09-25       Impact factor: 41.316

2.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Authors:  Keunchil Park; Eng-Huat Tan; Ken O'Byrne; Li Zhang; Michael Boyer; Tony Mok; Vera Hirsh; James Chih-Hsin Yang; Ki Hyeong Lee; Shun Lu; Yuankai Shi; Sang-We Kim; Janessa Laskin; Dong-Wan Kim; Catherine Dubos Arvis; Karl Kölbeck; Scott A Laurie; Chun-Ming Tsai; Mehdi Shahidi; Miyoung Kim; Dan Massey; Victoria Zazulina; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2016-04-12       Impact factor: 41.316

3.  A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

Authors:  A Lisberg; A Cummings; J W Goldman; K Bornazyan; N Reese; T Wang; P Coluzzi; B Ledezma; M Mendenhall; J Hunt; B Wolf; B Jones; J Madrigal; J Horton; M Spiegel; J Carroll; J Gukasyan; T Williams; L Sauer; C Wells; A Hardy; P Linares; C Lim; L Ma; C Adame; Edward B Garon
Journal:  J Thorac Oncol       Date:  2018-06-01       Impact factor: 15.609

4.  Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.

Authors:  Vanita Noronha; Vijay Maruti Patil; Amit Joshi; Nandini Menon; Anuradha Chougule; Abhishek Mahajan; Amit Janu; Nilendu Purandare; Rajiv Kumar; Sucheta More; Supriya Goud; Nandkumar Kadam; Nilesh Daware; Atanu Bhattacharjee; Srushti Shah; Akanksha Yadav; Vaishakhi Trivedi; Vichitra Behel; Amit Dutt; Shripad Dinanath Banavali; Kumar Prabhash
Journal:  J Clin Oncol       Date:  2019-08-14       Impact factor: 44.544

5.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

6.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

Review 7.  Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.

Authors:  Xiuning Le; Monique Nilsson; Jonathan Goldman; Martin Reck; Kazuhiko Nakagawa; Terafumi Kato; Luis Paz Ares; Bente Frimodt-Moller; Katharina Wolff; Carla Visseren-Grul; John V Heymach; Edward B Garon
Journal:  J Thorac Oncol       Date:  2020-10-20       Impact factor: 15.609

8.  Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.

Authors:  Haruhiro Saito; Tatsuro Fukuhara; Naoki Furuya; Kana Watanabe; Shunichi Sugawara; Shunichiro Iwasawa; Yoshio Tsunezuka; Ou Yamaguchi; Morihito Okada; Kozo Yoshimori; Ichiro Nakachi; Akihiko Gemma; Koichi Azuma; Futoshi Kurimoto; Yukari Tsubata; Yuka Fujita; Hiromi Nagashima; Gyo Asai; Satoshi Watanabe; Masaki Miyazaki; Koichi Hagiwara; Toshihiro Nukiwa; Satoshi Morita; Kunihiko Kobayashi; Makoto Maemondo
Journal:  Lancet Oncol       Date:  2019-04-08       Impact factor: 41.316

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.